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Abstract
Calcium (Ca2+)-permeable AMPA receptors may, in certain circumstances, contribute to normal synaptic plasticity or
to neurodegeneration. AMPA receptors are Ca2+-permeable if they lack the GluA2 subunit or if GluA2 is unedited at
a single nucleic acid, known as the Q/R site. In this study, we examined mice engineered with a point mutation in
the intronic editing complementary sequence (ECS) of the GluA2 gene, Gria2. Mice heterozygous for the ECS
mutation (named GluA2+/ECS(G)) had a ~ 20% reduction in GluA2 RNA editing at the Q/R site. We conducted an
initial phenotypic analysis of these mice, finding altered current-voltage relations (confirming expression of Ca2+-
permeable AMPA receptors at the synapse). Anatomically, we observed a loss of hippocampal CA1 neurons, altered
dendritic morphology and reductions in CA1 pyramidal cell spine density. Behaviourally, GluA2+/ECS(G) mice
exhibited reduced motor coordination, and learning and memory impairments. Notably, the mice also exhibited
both NMDA receptor-independent long-term potentiation (LTP) and vulnerability to NMDA receptor-independent
seizures. These NMDA receptor-independent seizures were rescued by the Ca2+-permeable AMPA receptor antagonist
IEM-1460. In summary, unedited GluA2(Q) may have the potential to drive NMDA receptor-independent processes in
brain function and disease. Our study provides an initial characterisation of a new mouse model for studying the role
of unedited GluA2(Q) in synaptic and dendritic spine plasticity in disorders where unedited GluA2(Q), synapse loss,
neurodegeneration, behavioural impairments and/or seizures are observed, such as ischemia, seizures and epilepsy,
Huntington’s disease, amyotrophic lateral sclerosis, astrocytoma, cocaine seeking behaviour and Alzheimer’s disease.
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Introduction
Within the central nervous system (CNS), α-amino-3-hy-
droxy-5-methyl-4-isoxazolepropionic acid receptors
(AMPARs) mediate the majority of fast excitatory
neurotransmission [1]. AMPARs are tetrameric protein
complexes composed of differing combinations of four
subunits, denoted GluA1-GluA4 (also known as
GluR1–4 and GluRA-D, for a full review of AMPAR
architecture refer here [2]). Diversity of AMPARs is
created through several mechanisms including differing
subunit composition [3–6], posttranslational modifica-
tions [7, 8], alternative splicing [9] and a process known
as RNA editing [10–12], all of which can profoundly
alter AMPAR properties.
RNA editing at the Q/R site (position 607) of GluA2 is a
crucial editing event occurring in AMPAR subunits [10,
13, 14]. At this site, an adenosine to inosine (A-to-I)
editing event results in an exonically encoded CAG codon
being edited to a CIG in the pre-mRNA [14]. The CIG
codon is read as a CGG because the inosine, in most cases,
is interpreted as a G during translation [15], resulting in a
conversion of glutamine (CAG, i.e. Q) to an arginine
(CGG, i.e. R). The editing-induced amino acid change has
a profound impact: AMPARs containing edited GluA2(R)
(which appear to constitute a majority of total AMPARs
physiologically [4–6, 16]) are Ca2+-impermeable. This
likely occurs because the arginine is positively charged and
present in the pore-lining (M2) region [17] which, in
contrast to the uncharged glutamine, prevents Ca2+flux.
Alternatively, AMPARs that lack the GluA2 subunit (i.e.
that are assembled from homomeric or heteromeric com-
binations of GluA1, A3 and A4), or that contain unedited
GluA2(Q), are Ca2+-permeable [10, 18–22].
It is unclear why this GluA2 editing process has
evolved [23–25], especially considering GluA2 Q/R site
editing is ~ 99% efficient in the healthy adult brain.
However, it is highly conserved [26, 27], hinting at a
strong selective pressure for retaining the editing process
[25, 28]. Although forced-edited mice expressing only
GluA2(R) appear normal [23], suggesting unedited
GluA2(Q) is not required for normal brain development
and function, we have previously argued that unedited
GluA2(Q) may have unrecognised physiological roles
when present in mature AMPARs [10]. Furthermore, a
decrease in editing efficiency has been observed in several
human neurological conditions including Alzheimer’s dis-
ease [29–31], schizophrenia [30], Huntington’s disease
[30], amyotrophic lateral sclerosis [32], astrocytoma [33],
ischemia [34] as well as cocaine seeking behaviour in rats
[35] (for a review see [36]). These findings suggest a
decrease in GluA2 Q/R site editing efficiency (leading to
increased proportions of unedited GluA2(Q) subunits,
relative to edited GluA2(R)), may play a role in the
aetiology of these conditions.
Supporting this hypothesis, several seminal studies have
described the phenotype of mice with forced expression of
varying levels of unedited GluA2(Q). In these studies,
mice were genetically engineered with deletions of the
Gria2 intronic editing complimentary sequence (ECS) that
is necessary for Q/R site RNA editing [37–39]. The mice
exhibited severely compromised phenotypes including a
propensity for seizures, premature mortality, synaptic
transmission abnormalities and hippocampal cell death
[37–39] (also see a study in zebrafish [40]). The seizures
and premature mortality are reminiscent of adenosine
deaminase acting on RNA 2 (ADAR2) knockout (KO)
mice (ADAR2 is the enzyme responsible for editing
GluA2 [41]). ADAR2 KO mice have a higher proportion
of unedited GluA2(Q) compared with edited GluA2(R)
and their phenotype can be significantly improved by the
forced expression of edited GluA2(R), suggesting unedited
GluA2(Q) is the primary driver of ADAR2 KO mouse
abnormalities [28, 42]. Furthermore, the expression of
unedited GluA2(Q) in adult mice renders hippocampal
neurons more vulnerable to ischemic insult [34, 43, 44].
Collectively, these studies hint to possible roles for un-
edited GluA2(Q) in the aetiology of several neurological
conditions, but there is much yet to learn and further
studies are needed. In particular, the phenotype of mice
genetically engineered to express higher proportions of
unedited GluA2(Q) has not yet been fully characterised,
in part because of the reduced lifespan of prior models,
leading to a lack of understanding of the role of unedited
GluA2(Q) in vivo. In this study we therefore generated a
new mouse line with a single point mutation in the ECS
that was previously found in vitro to regulate GluA2 Q/
R site RNA editing [45]. We have named this model
GluA2+/ECS(G). By introducing a single point mutation,
rather than removing the ECS entirely (as was done in
prior models [37–39]), we aimed to generate a model
with a more subtle phenotype that was amenable to
long-term phenotyping. We herein report that these
mice have reduced GluA2 Q/R site RNA editing and
provide initial anatomical, behavioural, electrophysio-
logical and seizure phenotyping, with a focus on the
hippocampus. We suggest that the mice will be of value
to the field for future studies investigating the role of
unedited GluA2(Q) in physiology and disease.
Materials and methods
Generation of mice
A targeting construct, including exons 9–12 of the Gria2
gene, was generated from DNA cloned from a 129S6
DNA genomic library (Fig. 1a). The final construct in-
cluded a single base pair guanine to cytosine mutation
within the ECS which altered the endogenous ECS se-
quence 5′-TTTGCTGCATA-3′ to the mutated sequence
5′-TTTGCTGGATA-3′. This particular nucleotide
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mutation was selected as it resulted in a significantly
higher proportion of unedited GluA2 RNA in an in vitro
study [45]. Additionally, a neomycin gene, surrounded by
loxP sites, was placed downstream of the ECS, while a thy-
midine kinase (TK) gene was inserted at the 3′ end of the
construct. The construct was electroporated into CCE
embryonic stem cells, which originate from 129SvEv mice.
Colonies resistant to G418 and ganciclovir were isolated.
An ES cell colony that contained the desired mutant allele
was identified. This ES cell colony was electroporated with
a Cre-expressing plasmid and re-plated in the absence of
G418 and ganciclovir, thus excising the neomycin and
leaving a single loxP site. Resulting ES cell colonies con-
taining the neomycin-deleted allele were chosen for
blastocyst injection into C57B6 embryos. Chimeric mice
were bred to 129S6 mice and offspring containing the mu-
tant allele were subsequently maintained in a 129S6 back-
ground. Mutant mice were designated GluA2+/ECS(G). In
all experiments, both heterozygous male and female mice
were used and compared with wildtype (WT) littermate
controls aged 8–10 weeks and experiments were per-
formed blind to genotype. Some experiments were con-
ducted with 36-week-old mice, as indicated in the
manuscript. The same mice were used for open field,
rotarod and fear conditioning, in that order. Mice used in
electrophysiology experiments were behaviorally naïve.
Genotyping
PCR of genomic DNA from tail biopsies was conducted
for genotyping analysis. PCR was routinely performed
with oligonucleotide primers for the Gria2 wild-type
allele (Forward: 5′-GTG TCT CTT GGG GAA GTT
CAA T-3′, and Reverse: 5′- TGA TAT ATT TCC CCT
CTT CTC AGC − 3′). For the targeted allele, a primer
was designed from within the loxP sequence with Re-
verse: 5′-TGC CCA CAT CTA AGA TTG TTG GAC-
3′). PCR product sizes for the wild-type and targeted al-
lele were 200 bp and 250 bp, respectively.
DNA sequencing
A single-step multiplex PCR targeted at amplifying exon
11 of Gria2 was utilized for confirmation of the muta-
tion to the ECS. (Forward: 5′-TGG CAC ACT GAG
GAA TTT GA-3′ and Reverse: 5′- TCA CAA ACA
CAC CCA TTT CCA-3′). The PCR assay was carried
out in a final volume of 50 μl containing 1 x Reaction
buffer, 200 μM dNTPs, 0.5 μM of each primer, 0.01 U of
Q5 Hot start High Fidelity DNA Polymerase (New Eng-
land Biolabs) and 1 μL of DNA template. PCR products
were purified using Qiaquick PCR purification kit (Qia-
gen). DNA sequencing was performed using an ABI
3130xl Genetic Analyzer (Applied Biosystems) with Big
Dye 3.0 chemistry, after which sequences were edited
and assembled using Finch TV (Geospiza Inc.).
RNA editing assay with sanger sequencing
Animals were anesthetized with isoflurane, brains were
rapidly dissected, and the hippocampus was isolated,
snap frozen (in dry ice) and stored at − 80 °C until re-
quired. Total RNA was isolated using a Maxwell® RSC
simplyRNA Tissue Kit (Promega, Cat# AS1340) and a
Maxwell® RSC Instrument (Promega), according to the
manufacturer’s instructions. As part of the protocol a
DNAse treatment step was performed. cDNA was syn-
thesized using SuperScript III (Invitrogen) and RNAseH
(Invitrogen) in a total volume of 20 μl. Both no-reverse
transcriptase and master mix controls were included to
ensure no contamination or cross-contamination was
present in the samples. PCR amplification was per-
formed across the editing region of GluA2 using the
cDNA template (Forward: 5′- CAGCAGATTTAGCC
CCTACG − 3′ and Reverse: 5′- AGCCGTGTAGGAGG
AGATGA − 3′), amplifying a 226 bp product. PCR prod-
ucts were run on a 2% agarose gel and bands were ex-
cised and purified using a QIAquick Gel Extraction Kit
(Qiagen), according to the manufacturer’s instructions.
20 ng of purified DNA was dried with 3.2 pmol of the
forward primer. Samples were sequenced at Garvan Mo-
lecular Genomics using an ABI 3130XL Genetic Ana-
lyser and were visualised using SnapGene Viewer. The
percentage of unedited RNA was quantified by measur-
ing the peak height of the A nucleotide at the Q/R site
of GluA2 sequences relative to the peak height of the G
nucleotide at this position using the formula: percentage
unedited templates = (peak height A/(peak height A +
peak height G)) × 100, as previously published [41, 46].
The peak heights were calculated using Image J (NIH).
BbvI RNA editing assay
Animals were anesthetized with isoflurane, brains were
rapidly dissected and the hippocampus was isolated, snap
frozen with isopentane and dry ice and stored at − 80 °C
until analysis. Total RNA was isolated using Trizol Re-
agent (Invitrogen) according to the manufacture’s proto-
col and subjected to DNAse treatment (Invitrogen).
cDNA was synthesized using SuperScript III (Invitrogen)
and RNAse-H (Invitrogen) in a total volume of 20 μl. PCR
amplification was performed across the editing region of
GluA2 using the cDNA template (Forward: 5′-TTC CTG
GTC AGC AGA TTT AGC C-3′ and Reverse: 5′-AGA
TCC TCA GCA CTT TCG-3′). PCR products were run
on a 1.8% agarose gel and the bands were excised and gel
purified using the QIAquick Gel Extraction Kit (Qiagen),
yielding 30 μl of product. The gel-purified products were
digested with 1 U of BbvI enzyme (New England Biolabs)
in a total volume of 20 μl for a total of six h at 37 °C. The
reaction was terminated at 65 °C for 20min. The products
were run on 10% TBE gels (Invitrogen). The bands were
quantified using Image J and expressed as a percentage of
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the unedited band (81 bp) divided by the unedited band
(81 bp) + the edited band (68 bp).
Kainic acid-induced seizure activity
8–10-week-old GluA2+/ECS(G) mice and littermate con-
trols were intraperitoneally injected with 10mg/kg kainic
acid (KA, Sigma) and were observed for 1 h following in-
jection. This dose was insufficient to induce seizures in
WT mice, but was sufficient to induce mild to moderate
seizures in GluA2+/ECS(G) mice. Where stated, mice were
injected immediately prior to KA administration with
AP-5 (20 mg/kg; Tocris) or IEM-1460 (7.5 mg/kg;
Tocris).
Seizure stage was assessed by the maximum score
within a five minute window, according to a modifica-
tion of the Racine scale: stage 0 - normal behaviour;
stage 1 - immobility; stage 2 - rigidity, whisker twitching;
stage 3 - forelimb pawing, head bobbing and tail whip-
ping; stage 4 - intermittent rearing and falling with fore-
limb/jaw clonus; stage 5 - continuous rearing and falling
> 30 s; stage 6 - generalized tonic-clonic seizures with
whole body convulsions; stage 7 death.
Electrophysiology
All tissue used for electrophysiology experiments was
derived from behaviourally naïve animals. Coronal CA1
slices (400 μm) were prepared using a vibratome
(VT1000S; Leica Microsystems) in ice-cold artificial
cerebrospinal fluid (ACSF) of composition: 126 mM
NaCl, 2.5 mM KCl, 1.4 mM NaH2PO4, 1.2 mM MgCl2,
2.4 mM CaCl2, 11 mM glucose and 25mM NaHCO3.
Slices were maintained (≥ 1.5 h) at 30–32 °C in a sub-
merged chamber containing carbogen equilibrated (95%
O2, 5% CO2) ACSF before being individually transferred
to a recording chamber (≥ 30min prior to recording)
and superfused continuously (2.5 ml.min− 1) with carbo-
gen equilibrated ACSF using a recirculation system. A
glass bipolar stimulating microelectrode (2–3MΩ, filled
with ACSF) was placed in the stratum radiatum.
For patch clamp experiments, CA1 neurons were visu-
ally identified using Dodt-tube optics on an upright
microscope (Olympus BX51). Whole-cell voltage-clamp
recordings were conducted via an Axopatch 700B patch
clamp amplifier, using an internal solution of the following
composition: 125mM CsMeSO3, 10mM CsCl, 5 mM
HEPES, 0.4 mM EGTA, 4mM NaCl, 1 mM MgCl2, 2 mM
MgATP, 0.3 mM NaGTP, 3mM QX314 and 0.1 mM
spermine (pH = 7.3; osmolarity = 280–285 mOsM). Series
resistance (< 25MΩ) was compensated by 80% and con-
tinuously monitored during experiments. Liquid junction
potentials of − 15mV were corrected. Electrically evoked
AMPA-receptor mediated excitatory postsynaptic currents
(EPSCs), obtained in the presence of the GABAA-receptor
blocker picrotoxin (100 μM) and the NMDAR antagonist
DL-AP5 (50 μM), were elicited once per 12 s. 1-naphthyl
acetyl spermine (Naspm, 50 μM) was bath applied to block
Ca2+-permeable AMPARs.
For long-term potentiation (LTP) experiments, field
excitatory postsynaptic potentials (fEPSPs) were recorded
via a glass microelectrode (2–3MΩ, filled with ACSF)
placed in the stratum radiatum 300–400 μm from the
stimulating electrode. fEPSPs were evoked once every 30 s,
at an intensity adjusted to produce fEPSPs with amplitudes
corresponding to ~ 50% of maximal responses. After
obtaining 20min of stable baseline fEPSPs, three trains of
high-frequency stimulation (HFS, 100 pulses at 100Hz,
inter-train interval of 10 s) to induce LTP, and fEPSPs were
recorded for another 60min.
Golgi staining
Mice were anesthetized with isoflurane and cervically
dislocated. Brains were stained using the FD Rapid
GolgiStain Kit (FD NeuroTechnologies) as per the man-
ufacturer’s recommendations. To analyse dendritic
morphology, Golgi-stained CA1 neurons were manually
traced at 100x magnification with Neurolucida (MBF
Bioscience) and total dendritic lengths were measured
and quantified using Neurolucida Explorer. Scholl ana-
lysis was performed with Neurolucida Explorer to dem-
onstrate the branching patterns of neuronal dendritic
trees. Spine density was assessed by counting the num-
ber of spines in 3 branches per neuron of branch orders
2–4. All protrusions no longer than 2 μm were counted
as spines if they were continuous with the dendritic
shaft. The spine density was defined as the number of
spines on 10 μm of dendritic length.
Immunohistochemistry
Immunohistochemistry was conducted as previously
described [47]. Tissue was cryosectioned at 40 μm
(Leica Microsystems). Free-floating sections were in-
cubated in mouse anti-NeuN (1:500; Merck Millipore)
for 72 h followed by overnight incubation in biotin-
labeled chicken anti-mouse secondary antibody (1:250;
Invitrogen). Immunolabeling was detected using HRP-
labeled avidin-biotin complex and 3.3′-Diaminobenzi-
dine substrate (DAB; Vector Laboratories).
Stereology
Design based stereology, using with Stereo Investigator 7
(MBF Bioscience), was used to estimate cell populations, as
previously described [47]. Briefly, estimates were conducted
on the dorsal hippocampus at the anteroposterior (AP) po-
sitions from between Bregma − 1.34mm and− 2.3mm. For
neuronal population estimates, a minimum 20 sampling
sites were sampled per section on a grid size of 84 μm×
60 μm and a counting frame size of 30 μm×30 μm. For all
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cell population estimates, a guard zone of 5 μm and a
dissector height of 10 μm were used. Each marker was
assessed at one in every sixth section, with a total of five
sections being sampled. Both the CA3 and CA1 regions of
the hippocampus were sampled.
Cobalt uptake
Mice were sacrificed, the brain rapidly removed and cor-
onal sections (400 μm) were cut with a vibratome (Leica
Microsystems) in ice cold Krebs solution buffer contain-
ing (in mM: 125 NaCl, 2.5 KCl, 26 NaHCO3, 1.25
NaH2PO4, 25 glucose, 2 CaCl2, 1 MgCl2) bubbled with
95% O2/5% CO2. Slices were allowed to recover for 1 h
in Krebs at 28 °C. Slices were transferred into a pre-
stimulation solution of low-sodium, low-calcium Krebs
solution containing (in mM: 50 NaCl, 2.5 KCl, 26
NaHCO3, 1.25 NaH2PO4, 25 glucose, 0.5 CaCl2, 2
MgCl2,) with 0.5 μM TTX (Tocris) and 100 μM AP-5
(Tocris). Control slices were pre-treated with Krebs con-
taining NBQX (20 μM; Tocris) or GYKI (100 μM;
Sigma). Slices were stimulated with kainate (20 μM;
Sigma) in the low-sodium, low-calcium Krebs solution,
with the addition of CoCl2 (1.5 mM). Slices were washed
in Kreb’s solution without divalent ions (in mM: 50
NaCl, 2.5 KCl, 26 NaHCO3, 1.25 NaH2PO4, 25 glucose)
containing EDTA (0.5 mM) for 10 min, before being in-
cubated in Kreb’s solution without divalent ions contain-
ing 0.12% NH4S for 5 min to precipitate intracellular
Co2+. Slices were then washed with Kreb’s solution with-
out divalent ions for 5 min and fixed in 4% paraformal-
dehyde overnight and equilibrated in 30% sucrose for
three days. Sections were cut in OCT (Scigen) at 40 μm
on a cryostat (Leica Microsystems) and mounted onto
gelatin-coated slides (Thermo Fisher Scientific).
For silver intensification, sections were incubated in
2% Na2WO4 for 10 min and then incubated in developer
solution (8 parts of AgNO3 solution: 1% Triton X-100,
7.5% CH3COOH, 30.3 mM Na-acetate, 2.94 mM AgNO3;
1 part of 5% Na2WO4; 1 part of 0.25% ascorbic acid) in
the dark for 15 min and washed in 2% Na2WO4, dried,
rinsed in 100% xylol, and coverslipped.
Co-Immunoprecipitations
Co-immunoprecipitation experiments were conducted
as previously described [16, 48, 49], with modification.
Mice were sacrificed, brains were rapidly dissected, and
the hippocampus was isolated, frozen with dry ice and
stored at − 80 °C until required. Tissue was homogenized
in 50 mM Tris-HCl (pH 7.4) with protease inhibitors
(Sigma). Cell membranes were sedimented by centrifu-
gation at 100,000 x g for 30 min at 4 °C. The pellet was
resuspended in 750 μl of 1% Triton X-100, 50 mM Tris-
HCl (pH 7.4) and 1mM EDTA followed by incubation
for 45 min at 37 °C. For co-immunoprecipitations, 3 μg
of antibody (GluA1, GluA2, GluA2/3, GluA4, GluA1 +
2/3, GluA2/3 + 4 or IgG) was incubated in 50 μL (1.5mg)
of Dynabead protein A (Invitrogen) according to manufac-
turer’s instructions. 105 μl of sample protein was incu-
bated with antibody-bound beads at RT for 30min with
gentle agitation. Protein was subjected to two rounds of
immunoprecipitations. Bound fractions from the first
round of immunoprecipitation were eluted using the pro-
vided elution buffer. LDS sample buffer and reducing
agent (Invitrogen) were added to bound and unbound
fraction samples followed by incubation for 10min at
70 °C prior to SDS PAGE and immunoblotting. The fol-
lowing AMPAR subunit-specific antibodies were used for
Western blotting: GluA1 (1:1000, Millipore), GluA2/3 (1:
1000, Millipore), GluA2 (1:1000, Millipore) and GluA3 (1:
1000, Cell Signaling). The percent of total AMPAR sub-
unit remaining in the unbound fraction was calculated
based on the standard curve created from control IgG
immunoprecipitated tissue.
Open field test
The open field test (OFT) was conducted as previously
described [47]. Briefly, mice were placed in an arena
(40x40cm) enclosed with clear plexiglass walls that was
situated in a large sound attenuating cubicle. Mice were
placed into the center of the arena and allowed to ex-
plore the test box for 10 min, while a computer software
program (Activity Monitor; Med Associates) recorded
activity via photobeam detection inside the testing
chambers. The total distance traveled over the course of
the 10 min was recorded.
Rotarod
Mice were placed on the suspended beam of the rotarod
facing away from the viewer for 5min. The rotarod was
started once all mice were placed on the beams and rotated
at a rate of 4 rpm which increased to 40 rpm over the course
of 5min. Animals were taken off the rotarod once they fell
to the catch tray below or after 5min had elapsed. The total
time spent on the beam was recorded. Animals were
exposed to the test once a day for three consecutive days.
Fear conditioning
Contextual fear conditioning was conducted as previously
described [47]. Briefly, training and testing took place in
cube-shaped fear-conditioning chambers (32 × 27 × 26 cm;
Med Associates Inc.) that had a clear plexiglass door, ceiling
and rear wall and grey aluminum side walls. Each chamber
had a removable grid floor, which consisted of 36 parallel
rods spaced 8mm apart. Positioned under the grid was a
removable aluminum tray for collection of waste. The rods
were connected to a shock generating and scrambling sys-
tem, which delivered a current to elicit a foot shock. This
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system was connected to and controlled by computer soft-
ware (FreezeFrame2, Actimetrics). A video camera, which
was positioned in front of the chambers, recorded the be-
havior of the mice during training and testing. On the con-
ditioning day, mice were placed into a fear-conditioning
chamber in which the environment (context) was con-
trolled. Mice were allowed time (3min) to explore the con-
text freely, prior to receiving a single moderate footshock
(0.5mA, 2 s). Following shock, all mice remained in the
chamber for 30 s and were then immediately returned to
their homecages. The following day, the mice were re-
exposed to the same context and behavior was recorded for
3min. Freezing was assessed as a measure of fear on all
days using a 4 s sampling method by investigators, who
were blind to the genotype. The number of observed
freezes was averaged and divided by the total number of
samples taken to yield a percentage of freezing. Data is pre-
sented as the average percentage of freezing during the 3
min period prior to shock delivery on conditioning day and
during the 3min test period on testing day.
Statistics
All statistical analysis was performed using GraphPad
Prism Version 7.0 (GraphPad Software, Inc). For seiz-
ure analysis, scores were square root transformed to
produce a normal distribution. Data sets were tested
for outliers using a Grubbs’ test. Differences between
means were assessed, as appropriate, by t-tests or
one/two-way ANOVAs (with or without repeated
measures, followed by Bonferroni post-hoc analysis).
Where repeated measures ANOVAs were performed,
we used the Geisser-Greenhouse correction (i.e. did
not assume sphericity). For t-tests, data sets were first
tested for normality (the D’Agostino & Pearson test
where possible, or the Shapiro-Wilk test if n’s were
too small for the D’Agostino & Pearson test), before
using either parametric or non-parametric tests, as
appropriate. For parametric tests, an F test for vari-
ance, calculated in GraphPad Prism Version 7.0, was
used to determine whether standard deviations were
equal between groups. If they were unequal, Welch’s
correction was applied to the t test. For non-
parametric tests, the Mann-Whitney test was used.
Statistical significance was defined at p < 0.05 and
presented as *p < 0.05, **p < 0.01, ***p < 0.001 and
****p < 0.0001. Results are displayed as mean ± stand-
ard deviation, unless otherwise indicated.
Results
GluA2+/ECS(G) have ~ 20% unedited GluA2(Q) RNA
A prior in vitro study identified several key residues in
the intronic ECS that are necessary for maintaining the
efficiency of GluA2 pre-mRNA Q/R site editing [45]. In
particular, when mutating a cytosine sitting within the
ECS of intron 11 to a guanine (see mutant B13M3 in
[45]), Higuchi et al., found < 1% of GluA2 transcripts
were edited. Building off this observation, we designed a
transgenic mouse in which the ECS was altered from the
endogenous sequence 5′-TTGCTGCATA-3′ (Fig. 1)a(i),
to the sequence 5′-TTGCTGGATA-3′.
Mice expressing the final mutant allele termed
GluA2+/ECS(G) (Fig. 1a(iii)) were maintained as hetero-
zygotes. Homozygote mutants were not viable. DNA
sequencing confirmed a guanine residue (G) in the
ECS of heterozygous GluA2+/ECS(G) mice, in the pos-
ition a cytosine (C) residue would otherwise occur in
the WT allele (Fig. 1b). DNA sequencing confirmed
no alteration to the Q/R site in the DNA of WT and
GluA2+/ECS(G) mice (Additional file 1a). Heterozygous
mice were identified by PCR of the downstream in-
tronic loxP sequence (Fig. 1c).
By sequencing mRNA transcripts, we determined
the efficiency of GluA2 RNA editing at the Q/R site
(Fig. 1d-e). We found 2.95 ± 0.48% of GluA2 is un-
edited at the Q/R site in the hippocampus of WT
mice (Fig. 1d). In contrast, GluA2+/ECS(G) mice
showed a significant increase in proportion of un-
edited GluA2(Q) RNA (20.3 ± 1.0% of total GluA2
transcripts) in the hippocampus (Fig. 1d; mean ± SD,
p = 0.0079 (Mann-Whitney test)), confirming the crit-
ical importance of the ECS sequence for regulating
normal GluA2 RNA editing in vivo. Editing assays
conducted via Sanger sequencing may yield higher
than expected editing rates in WT mice (editing rates
at the Q/R site of GluA2 are thought to be > 99% in
the adult brain [50]). Using a separate cohort of
GluA2+/ECS(G) mice we therefore conducted a second
RNA editing assessment using a standard BbvI restric-
tion enzyme-based assay. This assay confirmed the
significant increase in the proportion of unedited GluA2(Q)
RNA transcripts in GluA2+/ECS(G) mice (Additional file
1b-d). Q/R site RNA alterations were confirmed via RNA
sequencing in WT and GluA2+/ECS(G) mice (Fig. 1e and
Additional file 1a). We also found the editing changes did
not appear to grossly affect AMPAR subunit assembly
(Additional file 2).
GluA2+/ECS(G) have decreased body weight, premature
mortality and increased seizure susceptibility that is
NMDA receptor independent
Mice with reduced GluA2 Q/R site RNA editing have
previously been shown to exhibit decreased body weight
[38] and premature mortality, compared with WT lit-
termates [37, 38]. In this study, we found that
GluA2+/ECS(G) mice were outwardly normal at birth,
though they exhibited significant reductions in body
weight at 8 weeks of age (Fig. 2a; mean ± SD, t =
3.239, df = 15, p = 0.0046 (unpaired t-test)). A
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Kaplan-Meir survival curve (170 GluA2+/ECS(G) and
42 WT littermates) revealed GluA2+/ECS(G) mice
were significantly susceptible to premature death as
compared to WT littermates (Fig. 2b; χ2 = 77.07, df =
1, p < 0.0001), with a median survival of 9 weeks.
Premature mortality in GluA2+/ECS(G) mice was
possibly due to spontaneous seizures, which were
also observed.
The extended survival of GluA2+/ECS(G), in comparison
to previous mice with similar or greater GluA2 Q/R edit-
ing deficits [37, 38] allowed for an assessment of seizure
susceptibility in this model and, in particular, whether
seizure vulnerability is NMDAR-dependent. We injected
the excitotoxin, kainic acid (KA), or KA plus the Ca2+-per-
meable AMPAR antagonist, IEM-1460, intraperitoneally in
GluA2+/ECS(G) and WT mice. GluA2+/ECS(G) mice exhibited
significant seizure activity following a relatively low dose of
KA (10mg/kg), indicating enhanced neuronal excitability
in these mice (Fig. 2c; interaction F(60,708) = 4.097, p <
0.0001, genotype and treatment F(5,59) = 10.03, p < 0.0001,
time F(5.4, 319.3) = 43.22, p < 0.0001 (repeated measures two-
way ANOVA of square root transformed seizure scores,
Fig. 1 Generation of GluA2+/ECS(G) mice and GluA2 Q/R site editing efficiency analysis. a Schematic representation of the i) GluA2 WT allele, ii)
targeted GluA2+/ECS(G)neo allele and iii) the targeted GluA2+/ECS(G) allele, after the removal of the floxed neo cassette by Cre-mediated recombination.
Exons 10, 11 and 12 are shown (black boxes). Black arrows indicate loxP sites. The position of the cytosine to guanine mutation within the ECS is
indicated in red. White arrows indicate primer sets used for genotype analysis. b DNA sequencing of WT and GluA2+/ECS(G) mice confirmed the single
cytosine to guanine mutation in the ECS of heterozygous mice, as highlighted in yellow. c Genotype analysis of WT and GluA2+/ECS(G) mice by PCR
shows a band at 200 bp in WT and two bands at 200 bp and 250 bp in heterozygous mice. d GluA2+/ECS(G) mice exhibit a significant increase in the
proportion of unedited GluA2(Q) (n = 5/genotype; Mann-Whitney t-test). e Representative image of sequences from WT and GluA2+/ECS(G) mice. The
red arrow indicates the increased presence of A nucleotide indicating unedited RNA at the Q/R site of GluA2
Konen et al. Molecular Brain           (2020) 13:27 Page 7 of 19
followed by Bonferroni post-hoc analysis). Furthermore,
GluA2+/ECS(G) mice injected with IEM-1460, a specific in-
hibitor of Ca2+-permeable AMPARs (that are either GluA2
lacking, or containing unedited Q/R site GluA2 [51]), ex-
hibited reduced seizure behaviour that did not significantly
differ from WT mice (p > 0.05). In contrast, injection of
the NMDAR-antagonist, AP5, did not reduce seizure
vulnerability. Remarkably, the observed seizures in
GluA2+/ECS(G) therefore appear to be NMDAR-
independent. Combined, these results suggest that seizure
susceptibility is due to the activation of Ca2+-perme-
able AMPARs in GluA2+/ECS(G) mice.
GluA2+/ECS(G) have inwardly rectifying currents and
enhanced LTP which is AMPAR-dependent
Ca2+-permeable AMPARs show inwardly rectifying
current/voltage (I/V) relationships [52, 53]. We therefore
sought to establish whether GluA2+/ECS(G) mice exhib-
ited this phenotype. Previous mouse models with
reduced Q/R site RNA editing have illustrated altered
AMPAR hippocampal CA1 current rectification and
calcium permeability [37, 38]. It has generally been
thought this is due to a reduction in the availability of
edited GluA2, or of total GluA2 expression (i.e. an
increased proportion of GluA2 lacking, Ca2+ permeable
Fig. 2 Body weight, survival curve and seizure susceptibility analysis of GluA2+/ECS(G) mice. a GluA2+/ECS(G) mice exhibit reduced body weight, as compared
to WT littermates at 8 weeks of age (n= 6 GluA2 GluA2+/ECS(G) mice, 11 WT; unpaired t-test). b GluA2+/ECS(G) mice exhibit premature death and an
approximate median survival age of 9 weeks (n= 42 WT, 170 GluA2+/ECS(G) mice; Kaplan-Meier survival analysis). c GluA2+/ECS(G) mice exhibit increased
seizures following low-dose (10mg/kg) of intraperitoneal KA injection that is blocked by the Ca2+-permeable AMPAR antagonist, IEM-1460 though not by
AP5 (n= 16 (WT), 17 (GluA2+/ECS(G)), 7 (WT + IEM-1460), 11 (GluA2+/ECS(G) + IEM-1460), 3 (WT + AP5), 11 (GluA2+/ECS(G) + AP5); Repeated measures ANOVA).
Data in (a) represent mean ± SD and in (c) represent mean ± SEM. * = compared to WT, # = compared with GluA2+/ECS(G), ^ = compared with WT + IEM-
1460, ■ = compared with WT + AP5. One symbol, p < 0.05, two symbols, p < 0.01, three symbols, p < 0.001, four symbols, p < 0.0001
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AMPARs [37, 38]). However, this could also be due to
an increase in the proportion of AMPARs containing
unedited GluA2.
In the presence of AP5 (50 μM), AMPAR-mediated
EPSCs were readily evoked at − 70, 0 and + 40 mV in
CA1 neurons from both WT and GluA2+/ECS(G) mice
(Fig. 3a and b). While the evoked EPSCs displayed a lin-
ear I-V relationship in WT mice, the evoked EPSC I-V
relationship displayed inward rectification in GluA2+/ECS(G)
mice (Fig. 3a and b). Thus, the normalized evoked EPSC
amplitude at + 40mV was less in GluA2+/ECS(G) compared
to WT mice (Fig. 3b; interaction F(2,46) = 18.7, p < 0.0001,
genotype F(1,23) = 13.7, p = 0.0012, voltage F(2,46) = 878,
p < 0.0001). In addition, AMPAR-mediated evoked EPSCs
in GluA2+/ECS(G), but not WT mice, were sensitive to
NASPM, a synthetic analogue of Joro spider toxin, which
selectively blocks Ca2+-permeable AMPARs (Fig. 3c). On
average, NASPM (50 μM) inhibited evoked EPSC ampli-
tude by 41 ± 3% in GluA2+/ECS(G) mice, which significantly
differed to the 5 ± 4% inhibition observed in WT littermates
(Fig. 3c and d; p < 0.01).
GluA2-lacking AMPARs are also known to contribute
to NMDA receptor-independent LTP, particularly in the
CA1 region of the hippocampus [54, 55]. Whether
unedited GluA2(Q)-containing AMPARs contribute to
NMDA receptor-independent LTP is unknown. High
frequency stimulation (HFS) successfully induced LTP in
the CA1 region of both GluA2+/ECS(G) mice (180 ± 11%
of baseline, p < 0.05) and WT mice (123 ± 5% of baseline,
p < 0.05), but the magnitude of LTP was greater in the
GluA2+/ECS(G) mice (p < 0.001; Fig. 3d). To determine
the contribution of Ca2+-permeable AMPARs to LTP,
LTP experiments were also performed in slices pre-
incubated in the NMDA receptor antagonist DL-AP5
(100 μM). Under these conditions, HFS induced LTP in
the CA1 region of GluA2+/ECS(G) mice (144 ± 8% of base-
line, p < 0.01), but not WT mice (93 ± 6% of baseline,
p > 0.05; Fig. 3e). When slices were then pre-incubated
in both AP5 (100 μM) and the Ca2+-permeable AMPAR
antagonist IEM-1460 (50 μM), HFS did not induce LTP
in the CA1 region of either GluA2+/ECS(G) mice (96 ± 9%
of baseline), or WT mice (105 ± 7% of baseline; Fig. 3f).
These results suggest the NMDA-receptor independent
LTP observed in GluA2+/ECS(G) mice in the presence of
AP5 is dependent on Ca2+-permeable AMPARs. This
observation is interesting in the context of our earlier
observation that GluA2+/ECS(G) mice are vulnerable to
NMDAR-independent seizures (Fig. 2c).
Next, we utilised Cobalt (Co2+) labelling to directly
visualize the presence of Ca2+-permeable AMPARs in WT
and GluA2+/ECS(G) mice, similar to previous reports [56].
Acute hippocampal slices were stimulated by kainate in
the presence of AP5 and TTX. Sparse Co2+ staining was
observed in the CA3 hippocampal region of both
GluA2+/ECS(G) and WT mice (Fig. 3g), presumably in in-
terneurons that are known to express Ca2+-permeable
AMPARs [57, 58]. In contrast, GluA2+/ECS(G) mice showed
enhanced Co2+ staining compared to WTs in the CA1
hippocampal region (Fig. 3g). Collectively, these results in-
dicate CA1 neurons exhibit a larger influx of Ca2+ (and
Co2+) than CA3 neurons in GluA2+/ECS(G) mutant mice.
To confirm the influx of Co2+ was AMPAR mediated, we
illustrated that there was little Co2+ flux in WT hippocam-
pal slices incubated with AMPAR antagonists NBQX and
GYKI, or from GluA2+/ECS(G) mutant hippocampal slices
incubated with NBQX, GYKI and Ca2+-permeable
AMPAR antagonist JSTX (Fig. 3h).
Combined, the results presented in Fig. 3 indicate the
increased presence of Ca2+-permeable AMPARs in
GluA2+/ECS(G) mice. The Co2+ labelling assay suggests
the increased presence of Ca2+-permeable receptors is
specific to the CA1 region, mirroring the regional speci-
ficity of neuron loss in GluA2+/ECS(G) (see Fig. 4b and
Additional file 3a). Given subunit assembly does not ap-
pear to have been grossly altered in GluA2+/ECS(G) mice
(Additional file 2) we suggest the Ca2+-permeability of
AMPARs in GluA2+/ECS(G) mice is possibly a direct ef-
fect of increased unedited GluA2(Q).
GluA2+/ECS(G) have reduced dendritic density, lower
numbers of spines and hippocampal CA1, but not CA3,
neuron loss
Importantly, Brusa et al., reported neurodegeneration in
the CA3 of juvenile (P20) mice with Q/R site GluA2
editing deficits [37]. Additionally, Feldmeyer et al., re-
ported a reduction in CA3 pyramidal cell dendritic
length in P16 mice with reductions in GluA2 Q/R site
editing [38]. However, a quantification of synapse, neur-
onal or glial cell numbers has not yet been conducted
on tissue derived from young-adult, or adult mice with
genetically reduced levels of GluA2 Q/R site RNA edit-
ing. We therefore quantified both CA1 and CA3 neur-
onal, microglial and astrocyte numbers in young-adult
(8–10-week-old) GluA2+/ECS(G) mice. Furthermore, we
analysed both dendritic length and/or spine density, spe-
cifically in CA1 neurons.
To quantify hippocampal neurons, we used design-
based stereology to determine if NeuN+ cell populations
were altered in the CA1 and CA3 of GluA2+/ECS(G) mice
compared to WT controls (Fig. 4a and b). Intriguingly,
we found no differences in NeuN+ numbers in the CA3 of
WT vs. GluA2+/ECS(G) mice (Fig. 4b; mean ± SD, t = 0.24,
df = 8, p = 0.82 (unpaired t-test)). In contrast, we observed
a strong trend toward cell loss in the CA1 region of
GluA2+/ECS(G) mice compared to WT littermates at 8-10
weeks (Fig. 4b; mean ± SD, t = 2.3, df = 8, p = 0.0507 (un-
paired t-test)). In a cohort of GluA2+/ECS(G) mice surviv-
ing to 36 weeks we corroborated the CA1 neuron-
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Fig. 3 (See legend on next page.)
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loss specificity at 8-10 weeks by measuring NeuN+
cell numbers in the CA1 and CA3, finding signifi-
cant cell loss in the CA1 (Additional file 3a; mean ±
SD, t = 5.5, df = 4, p = 0.0055 (unpaired t-test)). Con-
sidering the prior report from Brusa et al., of CA3
damage, the CA1 specificity of neuron loss was
unexpected.
Next, we quantified total numbers of IBA1+ microglia
and GFAP+ astrocytes in 8-10-week-old mice, finding no
significant differences in the numbers of either microglia
located within the CA1 or CA3 neuronal cell layer
(Fig. 4c; CA1, t = 0.0203, df = 4, p = 0.9848 (unpaired
t-test), CA3, t = 0.8233, df = 4, p = 0.4566 (unpaired t-
test)) or astrocytes located within the CA1 or CA3
cell layer (Fig. 4d; CA1, t = 0.2831, df = 4, p = 0.7912
(unpaired t-test), CA3, t = 0.7163, df = 4, p = 0.5134
(unpaired t-test)) in GluA2+/ECS(G) mice compared to
WT controls.
Finally, we analysed dendritic length by Sholl analysis of
golgi-stained CA1 neurons. We measured this specifically
in hippocampal pyramidal CA1 neurons due to the
neuron loss in this region (Fig. 4e). Analysis of the main
effects illustrated there was an overall significant reduction
in the number of dendritic branching points at differing
lengths from the neuronal soma in GluA2+/ECS(G) mice
compared to WTs (Fig. 4e; interaction F (35, 576) = 1.341,
p = 0.093, genotype F (1, 576) = 25.22, p < 0.0001, distance
from soma, F (35, 576) = 62.76, p < 0.0001 (two-way
ANOVA)). Bonferroni post-hoc analysis did not reveal any
significant differences at individual branch points between
the groups. In addition, there was a significant reduction
of spine density on CA1 neurons from GluA2+/ECS(G)
mice, compared to WT littermates (Fig. 4f; t = 4.1, df = 43,
p = 0.0002 (unpaired t-test)).
Collectively, these results suggest a reduction in
GluA2 Q/R site RNA editing leads to hippocampal
CA1, but not CA3 neuron loss. The neuron loss does
not appear to be associated with a change in the total
numbers of microglia and astrocytes at 8-10 weeks,
however we note there are many further assessments
possible for determining if alterations in microglia
and astrocytes may be apparent and possibly
contributing to the phenotype of GluA2+/ECS(G) mice,
beyond simple cell counts. Furthermore, a GluA2 Q/R
site RNA editing deficit appears to lead to a reduc-
tion in both the number of dendritic branching points
and the total number of spines in CA1 hippocampal
pyramidal neurons in vivo.
GluA2+/ECS(G) have impaired motor function and deficits in
fear memory
Although mice with genetically reduced GluA2 Q/R
site RNA editing have survived to adulthood in prior
studies (with the caveat the average survival is still
dramatically reduced [38, 39]), these studies have con-
ducted only brief assessments of motor and cognitive
consequences of editing deficits, including open-field
behaviour [38] and spatial memory assessments [59]
(although the mice in [59] also had a GluA1 KO
alongside a GluA2 Q/R site editing deficit). Thus, we
assessed exploratory behaviour (open-field test), motor
coordination (rotarod) and hippocampal-specific
memory (context fear conditioning) of 8-10-week-old
GluA2+/ECS(G) mice, compared with WT littermates.
In the OFT, GluA2+/ECS(G) mice exhibited a significant
reduction in total distance travelled, compared with WT
controls (Fig. 5a; mean ± SD, t = 4.12, df = 16, p = 0.0008
(unpaired t-test)), indicating reduced exploratory behav-
iour. Furthermore, we observed impaired motor per-
formance in GluA2+/ECS(G) mice, as evidenced by poor
performance on the rotarod. Rotarod data from one
mouse was removed from the WT group after being
identified as a significant outlier using Grubbs’ test.
There was both a significant genotype and trial effect,
indicating differences between GluA2+/ECS(G) and WT
mice that were altered with subsequent trials (Fig. 5b;
interaction F(2, 32) = 1.69, p = 0.2011, genotype F(1,
16) = 8.86, p = 0.0090, trial F(1.9, 29.6) = 5.38, p = 0.0117
(repeated measures two-way ANOVA with Geisser-
Greenhouse correction)).
Next, we assessed hippocampal-specific memory in
GluA2+/ECS(G) mice. We conditioned both GluA2+/ECS(G)
and WT mice in a context fear conditioning paradigm
(pre-Shock and shock, Fig. 5c). 24 h later (Test, Fig. 5c),
(See figure on previous page.)
Fig. 3 AMPAR-mediated excitatory synaptic transmission and long-term synaptic plasticity in CA1 hippocampal neurons. a Averaged traces of
AMPA evoked EPSCs at − 70 and + 40mV in WT and GluA2+/ECS(G) mice. b Current-voltage (I/V) relationship of synaptic responses at − 70, 0 and
+ 40 mV in WT and GluA2+/ECS(G) mice (n=10 GluA2+/ECS(G) and 15 WT cells, normalized to evoked EPSC amplitude at − 70 mV; t-test). c Time plot
of evoked EPSC amplitude in the presence of the Ca2+-permeable AMPAR antagonist, Naspm (50 μM, n=7 GluA2+/ECS(G) and 8 WT cells),
normalized to the pre-Naspm baseline. Inset: Representative current traces of AMPA EPSCs (recorded at − 70 mV) before and during application of
Naspm in WT and GluA2+/ECS(G) mice. HFS induced LTP of fEPSPs in the hippocampal CA1 region of GluA2+/ECS(G) and WT mice, in (d) control
ACSF (n=5 GluA2+/ECS(G) and 7 WT slices; t-test), and in the presence of (e) the NMDA receptor antagonist DL-AP5 (100 μM; n=7 GluA2+/ECS(G) and
6 WT slices; t-test), or (f) DL-AP5 plus the Ca2+-permeable AMPAR antagonist IEM1460 (50 μM; n=5 GluA2+/ECS(G) and 6 WT slices; t-test). In (d – f)
fEPSP slope is normalized over 20 min prior to HFS. g Kainate induced Co2+ loading in the hippocampus revealed Co2+ uptake in the CA1 cell
layer of GluA2+/ECS(G) mice. h The AMPA and Kainate receptor antagonist NBQX (20 μM), and the non-competitive AMPAR antagonist GYKI 52466
(100 μM) sufficiently blocked Co2+ update in the CA1
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we re-exposed them to the conditioning context for 3
min in the absence of shock. The magnitude of ‘freezing’
was measured both pre-shock (on Day 1) and during the
test (on Day 2) to measure baseline and conditioned
fear, respectively. A significant interaction and main
effects of both genotype and test session occurred,
suggesting that both genotype and test session affected
fear, and that the former influenced the latter (Fig. 5c;
interaction F(1,28) = 59.45, p < 0.0001, genotype F(1,
28) = 59.93, p < 0.0001, trial F(1,28) = 63.79, p < 0.0001
(two-way ANOVA)). Bonferroni post-hoc analysis re-
vealed no significant differences in pre-shock freezing
between genotypes, suggesting no baseline fear alter-
ations in mutant mice. However, during test day, Bonfer-
roni post-hoc analysis illustrated WT mice display
significantly more freezing than GluA2+/ECS(G) mice (p <
0.0001). Furthermore, pre-shock and test freezing did
not differ significantly in GluA2+/ECS(G) mice suggesting
Fig. 4 Altered Hippocampal dendritic morphology and neural populations. a NeuN+ cells in the hippocampus (10x magnification) and CA1 region
(100x magnification) of WT and GluA2+/ECS(G) mice. b Cell loss was suggested in the CA1 but not CA3 region of the hippocampus in young adult
GluA2+/ECS(G) mice as compared to WT littermates (n=5 mice/genotype; unpaired t-test). c GFAP+ cell quantification in the CA1 and CA3 of
GluA2+/ECS(G) mice as compared to WT littermates (n=3 mice/genotype). d IBA1+ cell quantification in the CA1 and CA3 of GluA2+/ECS(G) mice as
compared to WT littermates (n=3 mice/genotype). e Inset: Representative traces of CA1 hippocampal neurons from GluA2+/ECS(G) and WT littermates.
GluA2+/ECS(G) mice exhibit decreases in dendritic intersections compared to WT controls (n=3 neurons/brain, 3 brains/genotype (total 9 neurons/
genotype) (two-way ANOVA, * = significant main effect of genotype on distance from soma). f Inset: Representative images of CA1 apical dendritic
spines from GluA2+/ECS(G) and WT littermates. GluA2+/ECS(G) mice have significantly less spines compared to WT littermates (n= 3 dendrites/neuron, 3
neurons/brain, 3 (WT) and 2 (GluA2+/ECS(G)) brains/genotype (total 27 (WT) and 18 (GluA2+/ECS(G)) apical dendrites/genotype); unpaired t-test). All
experiments in Fig. 4 were conducted in 8–10-week-old mice. Data in (b), (c), (d) and (f) represent mean ± SD and in (e) represent mean ± SEM
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a deficit in fear expression consistent with impairment
of memory acquisition, consolidation and retrieval.
Combined, our results reveal severe hippocampal mem-
ory deficits and motor coordination in mice that express
unedited GluA2 at the Q/R site.
Discussion
In the present study, we report a new mouse line, called
GluA2+/ECS(G), with only a single point mutation in the ECS
site on intron 11 of the Gria2 gene. These GluA2+/ECS(G)
mice have reduced GluA2 Q/R site RNA editing, in-
ward rectifying AMPAR currents and altered AMPAR
Ca2+-permeability, as predicted. They also appear to show
grossly normal AMPAR subunit assembly. Meanwhile, the
phenotype we observed in the GluA2+/ECS(G) mice was, in
general, less severe than that observed in previous models
[37, 38]. We discuss our initial observations in these mice
below and note that they remain available for future study.
GluA2+/ECS(G) mice have a GluA2 Q/R site editing
deficiency and longer lifespans than previously published
models with editing impairments
Three seminal publications have previously charac-
terised genetically modified mice with reduced Q/R
Fig. 5 Locomotor, memory and learning deficits in GluA2+/ECS(G) mice. a GluA2+/ECS(G) mice exhibit significantly impaired locomotion in the
open field test (n=12 (WT) and 6 (GluA2+/ECS(G))). b GluA2+/ECS(G) mice demonstrate impaired motor coordination and skill learning on the
accelerating rotarod over three consecutive trials (n=11 in WT and 7 in GluA2+/ECS(G) group; Repeated Measures ANOVA, * = significant main
effect of genotype on performance). c No significant differences occurred in pre-shock freezing between WT and GluA2+/ECS(G) mice, however
GluA2+/ECS(G) mice exhibited significant memory and learning impairments on test day (n=9 (WT) and 7 (GluA2+/ECS(G)))
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site GluA2 RNA editing [37–39]. First, Brusa et al.,
created a GluA2 Q/R site editing dysfunction by re-
placing the editing complementary sequence (ECS)
and some surrounding DNA within intron 11 of the
GluA2 gene (Gria2) with a single loxP site [37]. This
resulted in mice with ~ 20% of unedited mature cyto-
plasmic GluA2 mRNA (see [37] for details). Second,
Feldmeyer et al., generated several more GM mice
with variable levels of editing (98%, ~ 27.8 and 8.7%
unedited [38]). In the same publication they also de-
scribed a transgenic mouse carrying multiple copies
of a GluA2 minigene (in addition to endogenous
Gria2 alleles and being expressed in a similar pattern
to the endogenous protein) which encoded an aspara-
gine (N) at the Q/R site. Third, Krestel et al.,
expressed a mutant from Feldmeyer et al., but con-
trolled the expression of this mutation temporally and
regionally [39]. In that study, large increases in un-
edited GluA2(Q) expression were restricted to the
forebrain, hippocampal CA1 and dentate gyrus (DG)
cells, and could be induced postnatally.
In both Brusa et al., and Feldmeyer et al., the mice
generally had dramatically reduced lifespans (<P21) and
were prone to spontaneous seizures. In Krestel et al.,
despite restricting unedited GluA2(Q) expression to
postnatal periods, these mice still displayed a high mor-
tality rate (albeit extended compared to constitutive
models [38]), with ~ 60% dying from seizures at P60 (~
8.5 weeks). In contrast to mice created by Brusa et al.,
and Feldmeyer et al., our constitutive mutant editing
deficient mouse exhibited extended survival (although
shortened compared with WT mice), with ~ 50% mortality
by the age of 9 weeks, but are similarly prone to spontan-
eous seizures. The mortality rates therefore appear more
akin to the model described by Krestel et al. Curiously, the
mice from Krestel et al., with forebrain unedited
GluA2(Q) expression (restricted to postnatal periods), ex-
hibit a spontaneous seizure phenotype and premature
mortality [39], which may suggest seizures are not solely
resulting from developmentally generated effects in the
various constitutively unedited GluA2 mice.
GluA2+/ECS(G) mice exhibit altered I/V relations and NMDA
receptor independent LTP, concomitant with NMDAR-
independent seizure susceptibility
As expected, through the demonstration of inward
rectifying current/voltage (I/V) relationships, we
identified the presence of Ca2+-permeable AMPARs
in the CA1 hippocampal region of GluA2+/ECS(G)
mice. Our findings are reminiscent of those from
previous GluA2 Q/R site editing deficient mouse
models [37–39]. The presence of Ca2+-permeable
AMPARs was further confirmed using Naspm (a se-
lective inhibitor of Ca2+-permeable AMPARs). We
also demonstrated enhanced LTP in GluA2+/ECS(G)
mice that was NMDAR-independent. Thus, Ca2+-per-
meable AMPARs, containing unedited GluA2(Q),
might activate pathways normally activated by
NMDARs, leading to increased neuronal excitability.
Our results also demonstrate an enhanced KA-
induced seizure susceptibility in GluA2+/ECS(G) mice
which, as assessed using NMDAR and AMPAR specific
inhibitors, can be largely NMDAR-independent. To the
best of our knowledge, susceptibility to status epilepti-
cus, induced by KA, has not previously been assessed in
mice with constitutively impaired GluA2 Q/R editing.
Importantly, AP5, an NMDAR antagonist, has previously
been illustrated to have effects in the CNS of rats and
mice, when administered peripherally, at equivalent doses
to that used here [60–69]. This suggests it is unlikely any
lack of effect of AP5 was caused by poor penetration into
the brain. Furthermore, we [55] and others [70–72] have
previously found CNS effects after peripheral administra-
tion of the AMPAR antagonist IEM-1460. We note that it
is possible our results may be partially explained by IEM-
1460 penetrating the brain more efficiently than AP5. This
will be important to rule out in future work.
The results we observed are generally different to
those observed in GluA2 knockout or knockdown mice.
Hippocampal knockdown of GluA2 in age P13 rats [73],
but not adult rats [73, 74] (or adult mice, as we have
previously illustrated [55]), leads to an enhanced seizure
phenotype in the presence of KA, supporting the concept
GluA2 downregulation contributes to seizures in young,
but not adult, animals [73]. Meanwhile, intriguingly,
GluA2 KO mice have less frequent absence seizures in re-
sponse to γ-Hydroxybutyric acid than controls [75].
Perhaps most intriguingly, our finding that
GluA2+/ECS(G) mice have NMDAR-independent seizures,
that are instead dependent on Ca2+-permeable AMPARs,
may have important clinical implications. Altered RNA
editing has been implicated in the aetiology of seizures
[76]. Meanwhile, NMDAR antagonists have had mixed re-
sults in treating seizures in humans, though they are pro-
posed as second line therapy for status epilepticus [77].
The effect of seizures on GluA2 RNA editing has not been
extensively studied and our results suggest the efficacy of
NMDAR antagonists may be limited if RNA editing is re-
duced. Our study provides an imperative to further assess
the concept that Ca2+-permeable AMPARs, particularly
those containing unedited GluA2(Q) subunits, could pro-
vide a novel target for seizure control in patients [78, 79].
GluA2+/ECS(G) mice have CA1 specific neuron loss and CA1
synapse loss
We found neuronal death was specific to the CA1 hippo-
campal region, with no evidence of degeneration in the
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CA3 region in adult GluA2+/ECS(G) mice, including in an
aged cohort (Additional file 3). The selectivity of the
degeneration seems consistent with, and may be explained
by, our Cobalt (Co2+) labelling results, which suggested a
greater concentration of AMPAR-dependent Ca2+-perme-
able cells in the CA1 compared to the CA3 region, a find-
ing that remains open for future investigation.
Our findings contrast to those illustrating dendritic
length reduction [38] and cellular [37, 38] degeneration
in the CA3 region of previous editing mutant mice and
from studies showing a lack of hippocampal degener-
ation in adult rats following either ADAR2 gene silen-
cing [34], which reduces Q/R site GluA2 editing, or after
overexpression of unedited GluA2(Q) in adults [43, 44].
Our results also contrast with a report that unedited
GluA2(Q) induces spine growth in pyramidal cells and
interneurons in vitro [80], since we found spine and
dendritic loss in adult GluA2+/ECS(G) mice. We cannot
explain why our findings are different, but it may reflect
differences in study design, particularly that our study
was in vivo. It is also not yet clear why GluA2+/ECS(G)
mice have CA1, but not CA3 neuron loss. CA3 injury
and basal dendrite length reductions were previously ob-
served in the young (<P20) GluA2 Q/R editing mutant
mice that had prolonged seizure episode and shorter
lifespans than GluA2+/ECS(G) mice [37, 38]. Thus, CA3
damage could be explained by the severe seizure pheno-
type observed in these models. We also note these prior
studies did not perform stereological cell counting, as
performed in this study and that the design of the
mutant mice differs in that these prior models had
complete removal of the ECS.
The regional sensitivity to unedited GluA2(Q) could
be explained by the higher expression of GluA2 and
AMPARs in the CA1, compared with the CA3 and DG
[81, 82] and, as suggested above, it is consistent with the
finding of greater cobalt staining in the CA1 versus CA3
region. Our finding of CA1 neuron loss is also consistent
with studies illustrating unedited GluA2(Q) expression
can reduce the threshold for CA1 damage following an
acute insult, such as ischemia [34, 43, 44]. In summary,
although we cannot completely explain the CA1, but not
CA3 neurodegeneration in GluA2+/ECS(G) mice, it is rea-
sonable to consider that increased levels of unedited
GluA2(Q) may differentially affect these populations,
particularly in the absence of neurotoxic insults.
GluA2+/ECS(G) mice have impaired motor function and
deficits in fear memory
GluA2+/ECS(G) mice exhibited deficits in open field
behaviour. The impairment was possibly driven by a re-
duction in motor coordination, as exhibited by a reduced
ability to perform the rotarod task. The observation of
motor deficits in GluA2+/ECS(G) mice was not wholly
unexpected, not only due to these deficits previously be-
ing reported in GluA2 Q/R site editing deficient mice
[38] (including in ADAR2 knockdown mice, which also
have motor neuron degeneration [83, 84]), but also be-
cause of well-established evidence of GluA2 Q/R site
editing deficiencies in the spinal motor neurons of spor-
adic ALS patients [85]. Any future work would benefit
from a thorough characterisation of motor deficits, or
assessments of motor neuron cell numbers in
GluA2+/ECS(G) mice.
The hippocampal fear memory deficit we observed,
using the hippocampal-dependent context fear condi-
tioning paradigm, is likely the result of hippocampal syn-
aptic plasticity deficits (Fig. 3), CA1 spine and neuron
loss (Fig. 4), or a combination of both. In the context of
studies implicating GluA2 Q/R site editing deficits in
AD [29, 30], our results provide some evidence to
suggest alterations in the proportion of GluA2 Q/R may
be capable of aetiologically driving hippocampal learning
and memory deficits in dementia, if present in neurons
of affected individuals.
We note that GluA2 KO mice have reduced motor
coordination on the rotarod [54] and GluA2 lacking
receptors can play a role in LTP [54, 86] and NMDAR-
independent hippocampal-specific learning [55]. However,
we have only undertaken preliminary characterisations of
the GluA2+/ECS(G) mice in this study and much more
detailed assessments may be valuable in future to tease
out the phenotypic differences from GluA2 KOs.
Limitations
We cannot categorically state, nor do we rule out, that the
phenotype of GluA2+/ECS(G) mice may be partially
explained by Ca2+-signalling through GluA2-lacking
AMPARs. However, we consider it unlikely: homomeric
unedited GluA2(Q) receptors are known to be delivered
to synapses ex vivo [44], recombinant unedited GluA2(Q)
containing AMPARs rapidly replace native AMPARs [87],
GluA2(Q) homomers are readily trafficked to the cell sur-
face and enable CA1 LTP [88] and unedited GluA2(Q)
containing receptors are functional [18–20, 87]. Further-
more, notwithstanding our detection method may not be
sensitive enough to detect small changes, GluA2+/ECS(G)
mice do not show gross alterations in AMPAR subunit as-
sembly (Additional file 2), in contrast to GluA2 KO mice
[49]. We note our preliminary evidence is insufficient to
draw strong conclusions, other than a lack of gross
changes in receptor assembly.
Additionally, the cell loss we observe in the mice is rem-
iniscent of the effects of unedited GluA2(Q) expression
in vitro: viral-mediated expression of unedited GluA2(Q)
in primary neurons renders these neurons specifically sus-
ceptible to AMPA-induced toxicity, in comparison with
cells expressing GluA1 or GluA2(R) [89]. Meanwhile, we,
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and others, have previously shown GluA2 knockdown or
knockout does not lead to hippocampal cell loss [23, 54,
55, 74], unlike that seen in the present study (although we
note contrary findings [90, 91]).
We note also that the neurodegeneration we have
observed may represent a neurodevelopmental deficit
induced by unedited GluA2(Q), a theory supported by
findings that overexpression of unedited GluA2(Q) in
adult rats does not lead to acute hippocampal neurotox-
icity [34, 43, 44]. However, as noted earlier, inducible
expression of unedited GluA2 in adult mice does lead to
seizures [39], suggesting that the seizure vulnerability is
not solely a developmental defect.
Our findings, placed in the context of prior studies
illustrating unedited GluA2(Q) containing AMPARs are
present at the cell surface, are functional and contribute
to AMPAR signalling, make it reasonable to suggest un-
edited GluA2(Q) incorporation into AMPARs is con-
tributing to the increased AMPAR Ca2+-permeability,
enhanced NMDAR-independent LTP, CA1 specific-
neuron loss and behavioural deficits in GluA2+/ECS(G)
mice.
Conclusions and future directions
The current study provides an initial characterisation of
GluA2+/ECS(G) mice. Unedited GluA2(Q) expression could
influence GluA2 trafficking [92], maturation or AMPAR
tetramerization [50]. At present, we have evidence from
GluA2+/ECS(G) mice, provided in Additional file 2, that
AMPARs may be forming and trafficking normally, but
the data is an initial characterisation only. A comprehen-
sive and sophisticated analysis of gene and protein expres-
sion of GluA2, other GluAs, and the myriad of proteins
implicated in GluA2 RNA editing, trafficking and AMPAR
assembly, as well as trafficking and surface expression ana-
lyses, would be of value in future work. Future investiga-
tions should also consider unedited and edited GluA2
may have unique regional and temporal effects within dif-
ferent populations of cells and perhaps even within the
same population of cells [93, 94].
The observations in the current study provide further
support to the idea [34, 84] that unedited GluA2(Q) may
be a therapeutically relevant target for preventing neuro-
degeneration and behavioural impairments in a range of
neurological conditions and, given the results of this
study, NMDAR-independent seizures. This is, of course,
also implied by the reduced GluA2 Q/R site editing
efficiency in several neurological conditions including
Alzheimer’s disease [29–31], schizophrenia [30],
Huntington’s disease [30], amyotrophic lateral sclerosis
[32], astrocytoma [33], stroke [34] and cocaine seeking
behaviour in rats [35] and by prior observations that
overexpression of ADAR2, or overexpression of edited
GluA2, can provide therapeutic benefit in some models
[34, 35, 84]. GluA2+/ECS(G) mice may therefore offer a
new valuable tool for the community going forward and
will be made readily available for further study.
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Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1: (A) Q/R site DNA and mRNA sequences. DNA
sequencing of the Q/R site revealed the CAG codon in both the WT and
GluA2+/ECS(G), indicating no alteration to the site. cDNA sequencing of the
site revealed the CGG codon in WT mice, and a marked increase in
adenosine in GluA2+/ECS(G) at the CGG codon, confirming the RNA editing
assay results in GluA2+/ECS(G) mice. (B) Schematic representation of GluA2
cDNA BbvI digestion. The restriction digest produced 2 bands for edited
GluA2 (225 bp and 68 bp) and 4 bands for unedited GluA2 (225 bp, 144
bp, 81 bp and 68 bp). (C) BbvI restriction enzyme digest of PCR product
from WT and GluA2+/ECS(G) mice cDNA. (D) BbvI digestion assay results:
GluA2+/ECS(G) mice exhibit a significant increase in unedited GluA2 at the
Q/R site (n = 3/genotype; unpaired t-test).
Additional file 2: Schematic representation of the co-
immunoprecipitation assay and unbound and bound fraction data. (A)
Co-immunoprecipitations were performed by utilising the Dynabead®
protein A Immunoprecipitation kit. Dynabead protein A provided was
allowed to bind for 20 min with gentle agitation. Following washing,
protein sample was added and incubated at RT for 30 min with gentle
agitation. The sample was removed via the provided magnet and the
unbound fraction (round 1) was kept. The bound fraction was eluted with
the provided elution buffer. The unbound fraction was subjected to
another round of immunoprecipitations and subsequent to this the
fraction (unbound fraction round 2) was used for SDS gel electrophoresis
to identify associated AMPA subunits using the appropriate antibody. (B)
AMPA receptor subunits remaining after immunoprecipitation of hippocampal
homogenates from GluA2+/ECS(G) and WT mice (n = 3/genotype; t-test). (C) Co-
immunoprecipitation bound fraction analysis revealed correct protein binding.
The co-immunoprecipitation bound fraction was a result of one round of
precipitation with the Protein A kit, and reveals significant binding of the
appropriate proteins in the respective blots. This corresponds to the absence
of the respective proteins in B, and shows a correct procedure. The bound
fraction cannot be quantified. This is because, as is often the case, two rounds
of immunoprecipitation were required to pull down greater than 95%. Lower
band represents elution of the antibody.
Additional file 3: (A) Significant cell loss in the CA1 but not CA3 region
of the hippocampus in 36-week-old adult GluA2+/ECS(G) mice as com-
pared to WT littermates (n = 3/genotype; unpaired t-test). (B) IBA1+ cell
quantification in the CA1 and CA3 of 36-week-old GluA2+/ECS(G) mice as
compared to WT littermates (n = 3/genotype).
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